DrugPatentWatch Database Preview
Ripretinib - Generic Drug Details
» See Plans and Pricing
What are the generic sources for ripretinib and what is the scope of patent protection?
Ripretinib
is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ripretinib has twenty-seven patent family members in ten countries.
Summary for ripretinib
| International Patents: | 27 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 11 |
| Clinical Trials: | 2 |
| Patent Applications: | 5 |
| DailyMed Link: | ripretinib at DailyMed |
Recent Clinical Trials for ripretinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Deciphera Pharmaceuticals LLC | Phase 1 |
| Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
US Patents and Regulatory Information for ripretinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ripretinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2007296450 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008034008 | Start Trial |
| Brazil | PI0716981 | Start Trial |
| China | 101553232 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
